文献速递肝病消化道肿瘤与早癌

核苷(酸)类似物治疗对慢性乙型肝炎患者肝内胆管癌风险的影响

Effect of Nucleos(t)ide Analogue Therapy on Risk of Intrahepatic Cholangiocarcinoma in Patients With Chronic Hepatitis B.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-09-22

基于台湾全民健康保险研究数据库的全国性长期队列研究,纳入185,843例慢性HBV感染者,经倾向评分1:1匹配后比较10,062例核苷(酸)类似物治疗组与护肝药未治疗组的肝内胆管癌风险。治疗3年与5年累积发病率均显著低于未治疗组,多变量分析显示治疗与肝内胆管癌风险降低独立相关(HR 0.44)。

要点

  • 核苷(酸)类似物治疗与慢性乙型肝炎患者肝内胆管癌风险降低独立相关,HR为0.44。
  • 治疗3年累积发病率1.28%,未治疗组3.14%;5年分别为1.53%与4.32%。
  • 高龄(每年HR 1.05)与肝硬化(HR 2.80)与肝内胆管癌风险升高独立相关。

核心结论

  • 台湾全国性长期队列研究显示,慢性HBV感染的核苷(酸)类似物治疗与肝内胆管癌风险降低显著相关。

研究设计与样本

  • 全国性长期队列研究,使用台湾全民健康保险研究数据库,纳入2003年10月1日至2012年12月31日期间185,843例慢性HBV感染患者。
  • 排除合并丙型肝炎病毒、HIV或其他肝炎相关病毒、肝吸虫、胆石病、胆管炎、先天性胆道异常、胆道手术或癌症等混杂疾病患者。
  • 识别10,062例接受核苷(酸)类似物治疗的患者(治疗组),以倾向评分1:1匹配接受护肝药的患者(未治疗组)。

主要发现

  • 治疗3年肝内胆管癌累积发病率治疗组为1.28%(95%CI 0.56-2.01),未治疗组为3.14%(95%CI 2.02-4.27),治疗组显著低于未治疗组。
  • 治疗5年肝内胆管癌累积发病率治疗组为1.53%(95%CI 0.73-2.33),未治疗组为4.32%(95%CI 2.96-5.6869),治疗组显著低于未治疗组。
  • 多变量回归分析中,核苷(酸)类似物治疗与肝内胆管癌风险降低独立相关(HR 0.44;95%CI 0.25-0.78;P=.005)。
  • 高龄(每年HR 1.05;95%CI 1.03-1.07)与肝硬化(HR 2.80;95%CI 1.52-5.1415)与肝内胆管癌风险升高独立相关。
  • 敏感性分析验证了核苷(酸)类似物治疗与肝内胆管癌风险降低之间的关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Chronic infection with hepatitis B virus (HBV) increases risk of intrahepatic cholangiocarcinoma (ICC), but it is not clear whether antiviral therapy reduces risk. We investigated the association between nucleos(t)ide analogue therapy and ICC risk. METHODS: We performed a nationwide long-term cohort study using Taiwan's National Health Insurance Research Database to obtain data on 185,843 patients with chronic HBV infection from October 1, 2003 through December 31, 2012. We excluded patients with confounding disorders such as infection with hepatitis C virus, HIV, or other hepatitis-associated viruses; liver flukes; biliary stone diseases; cholangitis; congenital biliary anomalies; biliary tract surgeries; or cancer. We identified 10,062 patients who received nucleos(t)ide analogue therapy (the treated group), and used propensity scores to match them (1:1) with patients who received hepatoprotectants (the untreated group). Cumulative incidences of and hazard ratios (HRs) for ICC development were analyzed. RESULTS: The cumulative incidence of ICC was significantly lower in the treated group after 3 years of therapy (1.28%; 95% CI, 0.56-2.01) than in the untreated group (3.14%; 95% CI, 2.02-4.27) and after 5 years of therapy (1.53%; 95% CI, 0.73-2.33 vs 4.32% in untreated group; 95% CI, 2.96-5.6869). In multivariable regression analysis, nucleos(t)ide analogue therapy was independently associated with a reduced risk of ICC (HR, 0.44; 95% CI, 0.25-0.78; P = .005). Older age (HR 1.05 per year; 95% CI, 1.03-1.07) and cirrhosis (HR, 2.80; 95% CI, 1.52-5.1415) were independently associated with an increased risk of ICC. Sensitivity analyses verified the association between nucleos(t)ide analogue therapy and a reduced ICC risk. CONCLUSION: A nationwide long-term cohort study in Taiwan showed that nucleos(t)ide analogue therapy for chronic HBV infection is significantly associated with a reduced ICC risk.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lee TY, Hsu YC, Yu SH, et al. Effect of Nucleos(t)ide Analogue Therapy on Risk of Intrahepatic Cholangiocarcinoma in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2017. PMID: 28951229. doi:10.1016/j.cgh.2017.09.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。